Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with Gata2 deficiency, particularly diseases or disorders that involve any type of HDAC1 and/or HDAC2 expression. Such diseases include acute myeloid leukemia (AML)； familial myelodysplastic syndrome (MDS)； leukemia； sickle-cell anemia； beta-thalassemia； monocytopenia and mycobacterial infections； dendritic cell, nonocyte, B, and natural killer lymphoid deficiency； Emberger syndrome； asymptomatic neurocognitive impairment； mild neurocognitive disorder； and HIV- associated dementia.
